Allogeneic stem-cell transplantation following chimeric antigen receptor T-cell therapy for treatment of relapsed/refractory hematologic malignancy in children and young adults: a systematic review and meta-analysis.

In addition, both overall survival and leukemia-free survival rates showed a favorable trend toward the CAR T-cell+SCT group, respectively (hazard ratio, 0.44; 95% CI, 0.25–0.77; P =0.005; I 2 =0%; evidence, low; and hazard ratio, 0.29; 95% CI, 0.17–0.49; P <0.00001; I 2 =0%; evidence, low).

also in 466 other papers

The CAR T-cell+SCT group showed a trend toward higher complete remission (odds ratio [OR], 2.74; 95% confidence interval [CI], 0.88–8.54; P = 0.08; I 2 =57%; evidence, very low); lower mortality (OR, 0.58; 95% CI, 0.27–1.27; P =0.17; I 2 =0%; evidence, low), and decreased relapse (OR, 0.18; 95% CI, 0.06–0.56; P =0.003; I 2 =41%; evidence, low) rates than those who did not proceed to SCT.

also in 16,965 other papers